Archive for the ‘Gene Therapy Research’ Category

Vlad #39;s Grow Titan Genetics: Dawg #39;s Breath Ep. 3
Test grow for Titan Genetics: (Stardawg x Alien Kush f2) X Tennesee Hawg #39;s Breath Culled a couple and sexing the rest in cups.

By: Vladamyr

Read more here:
Vlad's Grow Titan Genetics: Dawg's Breath Ep. 3 - Video

WASHINGTON, March 1, 2013 /PRNewswire-USNewswire/ --Family Research Council (FRC) Senior Fellow Dr. David Prentice, a native Kansan, congratulated the Kansas state senate for passing S.B. 199, a bill that would establish the Midwest Stem Cell Therapy Center, a regional hub to advance and deliver adult and cord blood stem cell therapies to patients and serving as a resource for adult and cord blood stem cells for therapies. The Center would also inform professionals and the public about such therapies.

(Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO)

Dr. Prentice, a cell biologist who was selected by George W. Bush's Council on Bioethics to write a comprehensive review of adult stem cell research in 2004, testified before the Kansas Senate Committee on Public Health and Welfare in support of S.B. 199 on Feb. 25. Dr. Prentice additionally serves as adjunct professor of molecular genetics at the John Paul II Institute at the Catholic University of America, and formerly served as professor of life sciences at Indiana State University and adjunct professor of medical and molecular genetic at Indiana University School of Medicine.

The bill will now go to the Kansas House of Representatives for consideration.

In his testimony Dr. Prentice said:

"There are significant opportunities right now for Kansas to benefit from the establishment of a center of excellence specializing in the application of adult stem cell therapies for certain diseases, as well as educating physicians as well as the public about the advantages and availability of stem cell treatments.

"Kansas is moving forward as a potential leader in the area of adult and cord blood stem cell therapies. Estimates are that KU Med has done over 1,000 adult stem cell transplants, from bone marrow as well as a growing number from umbilical cord blood. These include stem cell transplants for various cancers and leukemias, but also initiating clinical trials to treat heart damage. Much more is possible.

"Kansas is well-positioned to become a leader in this area, and a global resource. The potential benefits for patients are incalculable. I urge you to support S.B. 199."

To read Dr. Prentice's testimony, click here: http://www.frc.org/testimony/testimony-of-dr-david-prentice-before-the-committee-on-public-health-and-welfare-kansas-senate

SOURCE Family Research Council

Read the original:
FRC's Dr. David Prentice Congratulates Kansas Senate for Passing Ethical Stem Cell Therapy Bill

SALT LAKE CITY, Feb. 28, 2013 /PRNewswire/ --Discgenics announces the successful completion of an animal study demonstrating safety and efficacy of its novel therapy for reducing back pain caused by degenerative disc disease. This product, known as Injectable Discosphere Cell Therapy (IDCT), features Discgenics' patented, allogeneic, human disc-derived stem cell technology. The study showed that after one injection of IDCT in degenerated discs there was a restoration of disc height and tissue architecture, while noting no inflammatory response.

Discgenics CEO Flagg Flanagan said, " We are very encouraged by the results of the small animal pilot study as it shows the initial safety and efficacy of IDCT, which is produced from adult human disc-derived stem cells.We are optimistic that these early results will be indicative of our therapy's performance in further animal studies and will accelerate us toward human clinical studies and, ultimately, to an FDA cleared product.We believe this technology will revolutionize the way back pain is treated." Discgenics is currently conducting further studies of safety and efficacy in multiple animal species to support future scientific publications and for use in gaining regulatory clearance.

About Discgenics, Inc.

Discgenics is a privately funded spinal therapeutics company that is utilizing adult human disc stem cells within a tissue engineering approach to treat patients debilitated by degenerative disc disease. News and other information on the company are available at: http://www.discgenics.com.

Read the original:
Discgenics Successfully Completes Pilot Efficacy Study of Injectable Discosphere™ Cell Therapy

Sixty years ago, scientists first discovered DNA, the structure in which a persons genes are encoded. Since then, our knowledge of the genome has revolutionized medicine. But when it comes to the U.S. legal system, important questions about what a gene is remain unsolved.

Here's one question: If a gene is patentable, does that mean a company can claim the rights to the gene's offspring?

The U.S. patent law was written in 1793, and it certainly didnt take into consideration a biological invention that could make endless copies of itself. So when Vernon Bowman, a 75-year-old farmer, decided to save some cash and buy seeds from a bulk grain distributor (seeds that were arguably protected by a patent), did he break intellectual property law?

Here's another: Do law enforcement need a search warrant to take a sample of a person's DNA? When the state of Maryland swabbed the cheek cells of Alonzo King when he was booked for assault, were they violating his Fourth Amendment right to privacy, since those cells would be crucial in convicting him of a crime committed six years earlier? To what extent is DNA protected private information?

As is often the case, U.S. law has still not caught up to the science. Three cases coming before the Supreme Court this term will have a significant impact on the future of genetics and the law. Each contains its own powerful question about genetics and what it means to criminal justice and industry.

Flickr/CodonAUG

Defining a gene can be difficult, but in the broadest sense its easyits a packet of information, says Dr. James P. Evan, a professor of genetics and medicine at the University of North Carolina. And if you have not really changed the content of that, the informational content, you dont deserve a patent.

Because Chakrabarty had actually created something novel, he won the case. But he was dealing in bacterial genetics. The question gets a little more confusing when it comes to human DNA, as well find in the upcoming case Association for Molecular Pathology v. Myriad Genetics.

Heres the background. If youre a woman, you really dont want to have the genes BRCA1 or BRCA2. That because 60 percent of female BRCA carriers develop breast cancer during their lifetime (compared with 12 percent of women in the population at large).

Myriad Genetics found a way to isolate the BRCA genes for testing, and have patented that technology. But they took the patent a step further. Claiming that they altered the BRCA genes to a degree not found in naturethat is, took them outside of a strand of DNAthey also filed a patent on the genes themselves.

More:
What Is a Gene And How Does it Apply to the Law? The Supreme Court Still Doesn't Know

Panel Discussion (Debate) Rehersal
Panel Discussion Topic: Genetic Engineering: Say No or Say Go?

By: Premo C.

Original post:
Panel Discussion (Debate) Rehersal - Video

Genetics and Genetic Engineering
In this live Grade 12 Life Sciences show we take a close look at Genetics Genetic Engineering. In this lesson we discuss inheritance of sex as well as haemophilia colour blindness as sex-linked characteristics. We look at the interpretation of pedigree diagrams and the importance of genetic engineering in medicine agriculture. Finally we discuss related ethics legislation as well as beliefs, attitudes values concerning genetic diseases. Download the Show Notes: http://www.mindset.co.za Visit the Learn Xtra Website: http://www.learnxtra.co.za View the Learn Xtra Live Schedule http://www.learnxtra.co.za Join us on Facebook: http://www.facebook.com Follow us on Twitter: twitter.com ( E00197263 )

By: MindsetLearn

Read the original here:
Genetics and Genetic Engineering - Video

Public release date: 28-Feb-2013 [ | E-mail | Share ]

Contact: Bill Schappert bschappert@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, February 28, 2013Sexting, the use of technology to send or receive sexually explicit messages, photos, or videos, is a relatively new trend and, in many cases, has legal implications. As many as 25-50% of young people may participate in sexting. A close-up look at the sexting practices of a group of urban ethnic minority youths is presented in an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available online on the Cyberpsychology, Behavior, and Social Networking website.

In fact, sexting is relatively common among ethnic minority youth, according to Melissa Fleschler Peskin, PhD and coauthors, University of Texas Health Science Center at Houston, School of Public Health. They calculated the prevalence of sexting based on data collected from more than 1,000 tenth graders from a large urban school district. They reported that 20% of students reported sending a nude or semi-nude picture or video or a sexual text messageany one of these considered a "sext"and more than 30% reported receiving a sext.

Additional, sexts were often shared with unintended recipients, and one-third of the youths reported sharing or receiving sexts that were meant to be private.

"In the relatively new discipline of cyberpsychology, we seek to explore the many challenges of current behavior that social networking potentiates. Certainly, such research enables us to better prepare for the behavioral changes that advances in Internet technology will continue to bring," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior, and Social Networking, from the Interactive Media Institute, San Diego, CA.

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is a peer-reviewed journal published monthly online with Open Access options and in print that explores the psychological and social issues surrounding the Internet and interactive technologies, plus cybertherapy and rehabilitation. Complete tables of content and a sample issue may be viewed on the Cyberpsychology, Behavior, and Social Networking website.

About the Publisher

Original post:
How common is 'sexting' among urban minority youth?

Public release date: 1-Mar-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, March 1, 2013Most adults and children with type 1 diabetes are not in optimal glycemic control, despite advances in insulin formulations and delivery systems and glucose monitoring approaches. Critical barriers to optimal glycemic control remain. A panel of experts in diabetes management and research met to explore these challenges, and their conclusions and recommendations for how to improve care and optimize clinical decision-making are presented in a white paper in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The paper is available free on the Diabetes Technology & Therapeutics website at http://www.liebertpub.com/dia.

Lead author Richard Bergenstal, MD, International Diabetes Center at Park Nicollet (IDC), outlines the critical issues impacting diabetes management as identified by the panel of luminaries in the field of diabetes during meetings facilitated by the IDC and funded by the Helmsley Charitable Trust. The team of authors emphasizes the critical need for standardization in the collection, reporting, visualization, and analysis of glucose monitoring data, and proposes clear and practical recommendations for implementing these solutions.

The expert panel included DTT Editor-in-Chief Satish Garg, MD, DTT Senior Editor Irl Hirsch, MD, and Andrew Ahmann, MD, Timothy Bailey, MD, Roy Beck, MD, PhD, Joan Bissen, Bruce Buckingham, MD, Larry Deeb, MD, Robert Dolin, MD, Robin Goland, MD, David Klonoff, MD, Davida Kruger, MSN, Glenn Matfin, MB ChB, MSc, Roger Mazze, PhD, Beth Olson, BAN, RN, Christopher Parkin, MS, Anne Peters, MD, Margaret Powers, PhD, Henry Rodriguez, MD, Phil Southerland, Ellie Strock, ANP-BC, William Tamborlane, MD, and David Wesley.

"Glucose monitoring is an essential part of effective diabetes management, and although it has come a long way, both health care providers and patients are frustrated that glucose data reporting has not been standardized," says Satish Garg, MD, Editor-in-Chief of the Journal and Professor of Medicine and Pediatrics at the University of Colorado Denver. "The recommendations reported in this white paper are a good first step toward improving health care outcomes in type 1 diabetes."

The white paper is accompanied by three Commentaries: one by DTT Editor-in-Chief Satish Garg, MD, one by Francine Ratner Kaufman, MD, Medtronic and Children's Hospital, Los Angeles, and one by Aaron Kowalski, PhD and Sanjoy Dutta, PhD, Juvenile Diabetes Research Foundation.

###

About the Journal

Diabetes Technology & Therapeutics is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics website at http://www.liebertpub.com/dia.

Read this article:
New guidelines for standardizing glucose reporting and optimizing clinical decision making in diabetes

Just a Friend Parody with biology lesson
This is a rap about biology to the beat of Biz Markie #39;s Just A Friend. We made this for extra credit in our biology class. Isn #39;t learning about genetics fun? 🙂

By: C-Ziggy Wiggy

Read more:
Just a Friend Parody with biology lesson - Video

Human intelligence is declining
Ever can #39;t help but think you #39;re surrounded by idiots? A leading scientist at Stanford University thinks he has the answer, and the bad news is things aren #39;t likely to get any better. Dr. Gerald Crabtree, a geneticist at Stanford, has published a study that he conducted to try and identify the progression of modern man #39;s intelligence. As it turns out, however, Dr. Crabtree #39;s research led him to believe that the collective mind of mankind has been on more or a less a downhill trajectory for quite some time. According to his research, published in two parts starting with last year #39;s #39;Our fragile intellect. Part I, #39; Dr. Crabtree thinks unavoidable changes in the genetic make-up coupled with modern technological advances has left humans, well, kind of stupid. He has recently published his follow-up analysis, and in it explains that of the roughly 5000 genes he considered the basis for human intelligence, a number of mutations over the years has forced modern man to be only a portion as bright as his ancestors. "New developments in genetics, anthropology and neurobiology predict that a very large number of genes underlie our intellectual and emotional abilities, making these abilities genetically surprisingly fragile," he writes in part one of his research. "Analysis of human mutation rates and the number of genes required for human intellectual and emotional fitness indicates that we are almost certainly losing these abilities," he adds in his latest report. From there, the ...

By: JonesMichaelBH

View post:
Human intelligence is declining - Video

Genetics punnett squares part 1

By: Ariana Koustas

Read more here:
Genetics punnett squares part 1 - Video

Genetics Punnett square part 3

By: Ariana Koustas

Read more:
Genetics Punnett square part 3 - Video

How to Pronounce Disomic
Learn how to say Disomic correctly with EmmaSaying #39;s "how do you pronounce" free tutorials. Definition of disomy (oxford dictionary): noun [mass noun] Genetics the condition of having a chromosome represented twice in a chromosomal complement. Derivatives disomic Pronunciation: /d #652; #618; #712;s #601; #650;m #618;k/ adjective Origin: late 20th century: from di-1 #39;two #39; + -some3 + -y3 http://www.emmasaying.com Take a look at my comparison tutorials here http://www.youtube.com Subscribe to my channel here : http://www.youtube.com

By: Emma Saying

Visit link:
How to Pronounce Disomic - Video

Genetics lesson starter
First attempt using iMovie - made to start lesson on dihybrid inheritance

By: Alex Gething

Read the original:
Genetics lesson starter - Video

"Hit Miss"
The Clinic for Special Children was established in 1989 as a non-profit medical service for Amish and Mennonite children with genetic disorders. The Clinic serves children by translating advances in genetics into timely diagnoses and accessible, comprehensive medical care, and by developing better understanding of heritable diseases. clinicforspecialchildren.org

By: rarediseaseday

Link:
"Hit

FearLess with ForeCYTE
Breast cancer claims the lives of 110 women every day in the United States. One in Eight women will be diagnosed with breast cancer in their lifetime. Clarity Women #39;s Health and Atossa Genetics, Inc. both leading providers in healthcare testing solutions, are focused on a novel cellular and molecular diagnostic risk assessment product for breast cancer, known as The ForeCYTE Breast Health Test. Through research, ForeCYTE has been developed to save the lives of millions of individuals and will transform the detection of breast cancer. Early detection of abnormal cell growth in the breast ensures you can take action to help prevent breast cancer. The ForeCYTE breast health test is an advancement in breast health that will help doctors save women #39;s lives and help us look forward to a future where we will be Fearless about breast cancer.

By: ForeCYTE

Continued here:
FearLess with ForeCYTE - Video

Remnant Fellowship TV - Put it into Practice - You Can Overcome - Season 2 - Episode 22
Remnant Fellowship TV presents: "Put it into Practice" Season 2 Episode 22 - Do you ever feel like you will never lose all your excess weight? There is hope! In a continuation of Season 2 Episode 21, Gwen shares that God did not make you overweight, it is not your genetics, and you too CAN be set free from overweight and obesity. This episode will teach you how to overcome excess weight and any other difficult situation by building your foundation on the solid rock of Jesus Christ. Hear from a testimony who lost 170 pounds through Weigh Down and learn how you, too, can lose your excess weight permanently and find restored health, peace, and joy. Special Guests: Jill Snapp and Candace Anger Copyright 2013 Remnant Fellowship, Weigh Down Ministries, and Gwen Shamblin For more lessons like this one or to visit a live worship assembly, go to http://www.RemnantFellowship.tv

By: RFChurch

Read this article:
Remnant Fellowship TV - Put it into Practice - You Can Overcome - Season 2 - Episode 22 - Video

MR. BUCKET (The Hidden)
#9658; #9658; #9658; Enjoy the video? Subscribe! bit.ly #9668; #9668; #9668; Download Here: http://www.hidden-source.com What is The Hidden? "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and traces of the experiments ...

By: SeaNanners

Continued here:
MR. BUCKET (The Hidden) - Video

The Banana Hotline
The Banana Hotline by Fallen Fruit RING RING!! The Banana Hotline is a 24 hour a day open platform for sharing your dreams and wishes. All the bananas in the world are the same genetics and are connected in the most basic way. They are distrubuted all over the world everyday for our entire lives. Bananas are like telephones, pick one up, hit record and send us your message! Fallen Fruit is a long-term art collaboration that began by mapping fruit trees growing on or over public property in Los Angeles. The collaboration has expanded to include serialized public projects and site-specific installations and happenings in various cities around the world. By always working with fruit as a material or media, the catalogue of projects and works reimagine public interactions with the margins of urban space, systems of community and narrative real-time experience.

By: DavidBurnsProjects

Continued here:
The Banana Hotline - Video

IOWA CITY, Iowa (AP) A growing number of universities are offering classes on personal genetics to educate students about a medical field that is becoming increasingly important as the price of genetic testing drops. Here's a look at the basics:

Q: What is genetic testing and genotyping?

A: A genetic test analyzes DNA to look for a specific gene to test for the presence of a condition, such as Huntington's disease. Genotyping goes far beyond that, analyzing several or even thousands of variants across an individual's full set of genes, known as the genome.

Q: How can you get such testing done?

A: Medical providers use the testing routinely. It helps them diagnose patients who have symptoms of a disease, screen newborn infants for disease risks, tell parents whether their unborn child will have a genetic condition, and determine the amount and type of medicine best suited for a patient.

But what is becoming more available and common is testing done by private companies marketing services directly to consumers, such as 23AndMe and AncestryDNA. These tests typically analyze thousands of different variants but do not look at the entire genome. The tests can cost $99 to more than $1,000, depending on the extent of testing done. 23AndMe and AncestryDNA require individuals to submit saliva samples, and initial results can be available within six weeks.

Q: What can the results show?

A: The results can show whether individuals are at increased risk for a range of diseases; whether they are a carrier for hundreds of genetic conditions; whether they are predisposed to have certain physical traits; where one's ancestors come from; how they may respond to certain drugs.

Q: What are some practical ways this can help?

A: The information can help diagnose potential health problems sooner. Individuals may be able to take steps to avoid behavior that may trigger health problems for which they know they're at risk. Couples who learn they are carriers for the same disease may conceive with egg or sperm donors to avoid passing it to children. Individuals may be able to identify and meet relatives they did not know.

Read the original post:
Q&A: The science behind personal genetics testing

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGI), a leader in oncology-focused personalized medicine, today announced it has received CLIA and New York State approvals for clinical use of its proprietary mature B-cell neoplasm array or MatBA (patent 13/475,034) for diffuse large B-cell lymphoma. MatBA-DLBCL will assist clinicians in the diagnosis and prognosis of DLBCL.

DLBCL is the most common form of non-Hodgkin lymphoma (NHL), a diverse group of hematological malignancies. An estimated 190,000 people in the United State suffer from DLBCL, and up to 24,500 new U.S. cases diagnosed each year, which accounts for up to 40% of all NHL cases. Newly-diagnosed patients have a median age of 64 years, and disease progression and outcomes vary widely, due in part to the genomic characteristics of each individual patients cancer. This creates a strong clinical need for accurate and molecularly-informed prognostic testing both at the time of initial diagnosis and throughout ongoing disease monitoring efforts to ensure selection of the best treatment plan for an individual patient. However, current prognostic modalities rely primarily on clinical features.

CGIs MatBA-DLBCL microarray provides clinicians with information on genomic alterations in DLBCL, including regions of gain and loss that are associated with disease outcome.

A research collaboration between the Memorial Sloan-Kettering Cancer Center and CGI using 87 patient samples, as well as the analysis of two open datasets including 171 samples (GSE11318, Lenz et al.) and 51 high risk samples (E-MEXP-3463, Taskinen) and other published datasets showed that:

CGI believes that it is the only laboratory to have a CLIA and New York State approved microarray for the genomic assessment of DLBCL. The MatBA-DLBCL Array CGH assay joins the DLBCL CompleteSM program offered by CGI, which includes a suite of esoteric tests used in the diagnosis, prognosis and clinical management of DLBCL patients. This newly-approved DLBCL test extends CGIs ongoing commitment to developing new diagnostic and disease management tools for some of the most costly and critical unmet needs in oncology today. MatBA-DLBCL joins MatBA-CLL (chronic lymphocytic leukemia) and MatBA-SLL (small lymphocytic leukemia) in CGIs suite of CLIA- and New York State-approved proprietary microarrays for the clinical management of underserved hematological malignancies.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and CAP accredited. In addition, we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey. The company has been built on a foundation of world-class scientific knowledge and IP in solid and hematologic cancers, as well as strong research collaborations with major cancer centers such as Memorial Sloan-Kettering and the National Cancer Institute.

CGIs dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new oncology tests. CGIs full-service cancer genetic practice and path to innovation with research makes for optimal patient care management. For further information, please see http://www.cancergenetics.com.

Here is the original post:
Cancer Genetics, Inc. Receives Regulatory Approvals for MatBA®-DLBCL, A Proprietary Microarray Test for the Diagnosis ...

AMES, IA--(Marketwire - Feb 28, 2013) - NewLink Genetics Corporation ( NASDAQ : NLNK ), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated 2012 financial results and reviewed key 2012 accomplishments.

"We have made significant progress during this past year.The enrollment rate in our pivotal phase 3 IMPRESS trial with our active cellular immunotherapy product candidate for resected pancreatic cancer, algenpantucel-L,has exceeded our original expectations.We initiated both a Phase 3 study in patients with locally advanced pancreatic cancer using algenpantucel-L, and a Phase 2B/3 adaptive design study to evaluate our active cellular immunotherapy using tergenpumatucel-L in patients with progressive or relapsed Stage IIIB/IV non-small cell lung cancer (NSCLC).In addition, weexpect to move our HyperAcute melanoma immunotherapy into controlled phase 2 studies in 2013.We are also expanding our HyperAcute immunotherapy platform to include different tumor types.Furthermore, weexpect to move the first of these into Phase 1 human studies in the second half of 2013," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink."Rapid enrollment rate in our pivotal phase 3 IMPRESS pancreatic cancer study should enable us to complete enrollment of this trial in the summer of 2013, ahead of our original schedule."

Full Year 2012 Financial Results

Financial GuidanceNewLink expects to end 2013 with about $40 million in cash, cash equivalents and marketable securities.

Recent Accomplishments

Upcoming ActivitiesNewLink expects to present at the following conferences:

Today's Conference Call and Webcast ReminderThe NewLink management team will host a conference call discussing the company's financial results and recent corporate developments on Thursday, February 28, 2013, at 10:00am EST.The call can be accessed by dialing 1-(877) 363-5052 (domestic) or 1-(914) 495-8600 (international) five minutes prior to the start of the call and providing the passcode 16064630.A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-(855) 859-2056 (domestic) or 1-(404) 537-3406 (international), providing the passcode 16064630.The replay will be available for two weeks from the date of the live call.

About HyperAcute Immunotherapy

NewLink's HyperAcute immunotherapy technology is designed to stimulate the human immune system by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals.This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, or Alpha-GT, which is expressed in the cells of lower mammals but not present in human cells.The presence of this enzyme results in the incorporation of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates, or Alpha-Gal, on the surface of expressing cells.Introducing Alpha-Gal expressing cells to the human immune system activates an immune response resulting from pre-existing antibodies against Alpha-Gal.Antibodies directed against the Alpha-Gal epitope are potentially the most abundant natural antibody in humans and represent approximately 1% of circulating human antibodies.

NewLink's HyperAcute cancer immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes Alpha-Gal epitopes.This exposure to Alpha-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on which Alpha-Gal is present by activating complement, an important component of the immune system capable of cell destruction.After destruction, NewLink believes the resulting cellular fragments bound by anti-Alpha-Gal antibodies are processed by the immune system to elicit an enhanced multi-faceted immune response to tumor-associated antigens common to both the immunotherapy and the patient's tumor cells.

Originally posted here:
NewLink Genetics Reports Fourth Quarter and Full-Year 2012 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Good Start Genetics, Inc.,an innovative molecular diagnostics company developing the new gold standard in carrier screening, announced today that it will present a company overview at the Cowen and Company 33rd Annual Health Care Conference at the Boston Marriott Copley Place. Don Hardison, president and CEO of Good Start Genetics, is scheduled to present at 9 a.m. on Tuesday, March 5.

Mr. Hardison will provide an overview of Good Start Genetics and its groundbreaking next-generation DNA sequencing based carrier screening service, as well as highlights from its first year on the market. Mr. Hardison will be available to meet with investors and media attending the conference.

Good Start Genetics recently announced that four separate abstracts related to its technology have been accepted for presentation at the upcoming annual meetings of the Pacific Coast Reproductive Society (PCRS) and the American Congress of Medical Genetics and Genomics (ACMG).

Since its national launch in April 2012, Good Start Genetics high-complexity, CLIA- and CAP-accredited laboratory has processed tens of thousands of test orders. The GoodStart Select next-generation gene sequencing technology detects common mutations in carriers across all 23 diseases recommended for testing by major medical societies as well as rare mutations that would go undetected by laboratories using older, traditional genotyping-based technologies. For example, most genotyping technologies detect about 100 mutations for cystic fibrosis (CF), while GoodStart Select detects 550 mutations.

Event

Date

Time

Place

About Good Start Genetics, Inc.

Continued here:
Good Start Genetics to Present at Cowen and Company 33rd Annual Health Care Conference

OMICS Group-Genetic Syndromes amp; Gene Therapy-7412-3-118
OMICS Group is an Open Access publication model that enables the dissemination of research articles to the global community. Thus, all articles published under Open Access can be accessed by anyone.

By: OMICSGroup I Articles

Continue reading here:
OMICS Group-Genetic Syndromes & Gene Therapy-7412-3-118 - Video

OMICS Group - Genetic Syndromes amp; Gene Therapy-7412-3-119
OMICS Group is an Open Access publication model that enables the dissemination of research articles to the global community. Thus, all articles published under Open Access can be accessed by anyone.

By: OMICSGroup I Articles

View original post here:
OMICS Group - Genetic Syndromes & Gene Therapy-7412-3-119 - Video